Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics (NQ: CORT )

29.00 +0.12 (+0.42%)
Streaming Delayed Price Updated: 11:56 AM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics

< Previous 1 2 3 4 5 6 Next >
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Analyst Expectations for Corcept Therapeutics's Future
Via Benzinga
Corcept Therapeutics's Return On Capital Employed Overview
Via Benzinga
Analyst Ratings for Corcept Therapeutics
Via Benzinga
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2023
Via Benzinga
Analyst Expectations for Corcept Therapeutics's Future
Via Benzinga
Corcept Therapeutics Announces Final Results of Tender Offer
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Short Volatility Alert: Corcept Therapeutics
On Tuesday, shares of Corcept Therapeutics (NASDAQ: CORT) experienced volatile short activity. After the activity, the stock price went up +1.66% to $22.02. The overall sentiment for CORT has been... 
Via Benzinga
Corcept Therapeutics Announces Preliminary Results of Tender Offer
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Initiates CATALYST Clinical Trial
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023
Via Benzinga
Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 7,500,000 Shares of its Common Stock
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2022 Audited Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2023
Via Benzinga
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation
From Corcept Therapeutics Incorporated
Via GlobeNewswire
EQUITY ALERT: Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation – CORT
From The Rosen Law Firm, P.A.
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
5 Most Cheapest Stocks In The Healthcare Sector: Bio-Techne, Mirati Therapeutics And More
The most oversold stocks in the healthcare sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Our 7 Top Biotech Stock Picks for 2023
Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023. 
Via InvestorPlace
Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Provides Miricorilant Clinical Development Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics's Earnings: A Preview
Corcept Therapeutics (NASDAQ:CORT) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.